{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:07:21Z","timestamp":1788955641272,"version":"build-2803163510"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pembrolizumab monotherapy is standard of care in first line treatment of patients with stage IV lung cancer and programmed death ligand 1 (PD-L1) expression \u2265 50%. Whether the higher levels of PD-L1 expression predict higher benefit from the treatment with pembrolizumab is still debatable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This trial analyzed clinical and pathological characteristics, overall response rate (ORR), and survival outcomes in patients with non-small cell lung cancer (NSCLC) and PD-L1 expression of \u2265 50% who received front line treatment with pembrolizumab in real-world setting. The aim was to evaluate does the level of expression influence survival endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-one consecutive patients were evaluated in this study. The median PFS for patients in this study was 12.0 months (95% CI, 7.7\u201316.2 months), and the median OS was 21.0 months (95% CI, 9.6\u201332.3 months). Based on PD-L1 status patients were divided into two groups. First one with PD-L1 expression of 50%\u201379%, and the second with expression over 80%. Gender distribution between the two groups (p = 0.029) and difference in stage of the disease (p = 0.039) were statistically significant. There was no significant difference in progression free survival (p = 0.548) and overall survival (p = 0.153) between two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This trial did not confirm relation between higher expression of PD-L1 and better survival outcomes. However, the pitfall of the trial was relatively small number of patients, so with the expansion of this real-world data (RWD) dataset future results might differ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2026-0050","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:26:04Z","timestamp":1788953164000},"page":"450-458","source":"Crossref","is-referenced-by-count":0,"title":["Real-world data survival outcomes of first line immunotherapy with pembrolizumab in high expressers with stage IV non-small cell lung cancer"],"prefix":"10.2478","volume":"60","author":[{"given":"Vladimir","family":"Stojsic","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Zaric","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Simurdic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomi","family":"Kovacevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darijo","family":"Bokan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena Djekic","family":"Malbasa","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Sarcev","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Stojanovic","sequence":"additional","affiliation":[{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"},{"name":"Faculty of Pharmacy, University Business Academy in Novi Sad , Novi Sad , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daliborka","family":"Bursac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Clinic for Thoracic Oncology, Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislava","family":"Nikolin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad , Novi Sad , Serbia"},{"name":"Oncology Institute of Vojvodina , Sremska Kamenica , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090905570684855_j_raon-2026-0050_ref_001","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-63. doi: 10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"key":"2026090905570684855_j_raon-2026-0050_ref_002","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48. doi: 10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"2026090905570684855_j_raon-2026-0050_ref_003","unstructured":"Goodarzi E, Sohrabivafa M, Adineh HA, Moayed L, Khazaei Z. Geographical distribution global incidence and mortality of lung cancer and its relationship with the Human Development Index (HDI); an ecology study in 2018. WCRJ 2019; 6: e1354. doi: 10.32113\/wcrj_20197_1354"},{"key":"2026090905570684855_j_raon-2026-0050_ref_004","doi-asserted-by":"crossref","unstructured":"Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci 2021; 22: 8661. doi: 10.3390\/ijms2216866","DOI":"10.3390\/ijms22168661"},{"key":"2026090905570684855_j_raon-2026-0050_ref_005","doi-asserted-by":"crossref","unstructured":"Xia L, Liu Y, Wang Y. PD-1\/PD-L1 Blockade Therapy in advanced non-smallcell lung cancer: current status and future directions. Oncologist 2019; 24(Suppl 1): S31-41. doi: 10.1634\/theoncologist.2019-IO-S1-s05","DOI":"10.1634\/theoncologist.2019-IO-S1-s05"},{"key":"2026090905570684855_j_raon-2026-0050_ref_006","doi-asserted-by":"crossref","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-29. doi: 10.1084\/jem.20090847","DOI":"10.1084\/jem.20090847"},{"key":"2026090905570684855_j_raon-2026-0050_ref_007","doi-asserted-by":"crossref","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015; 125: 3384-91. doi: 10.1172\/JCI80011","DOI":"10.1172\/JCI80011"},{"key":"2026090905570684855_j_raon-2026-0050_ref_008","doi-asserted-by":"crossref","unstructured":"Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1\/2 pathway from discovery to clinical implementation. Front Immunol 2016; 7: 550. doi: 10.3389\/fimmu.2016.00550","DOI":"10.3389\/fimmu.2016.00550"},{"key":"2026090905570684855_j_raon-2026-0050_ref_009","doi-asserted-by":"crossref","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-28. doi: 10.1056\/NEJMoa1501824","DOI":"10.1056\/NEJMoa1501824"},{"key":"2026090905570684855_j_raon-2026-0050_ref_010","doi-asserted-by":"crossref","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-50. doi: 10.1016\/S0140-6736(15)01281-7","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2026090905570684855_j_raon-2026-0050_ref_011","doi-asserted-by":"crossref","unstructured":"Reck M, Brahmer JR. Pembrolizumab in non-small-cell lung cancer. N Engl J Med 2017; 376: 997. doi: 10.1056\/NEJMc1615559","DOI":"10.1056\/NEJMc1615559"},{"key":"2026090905570684855_j_raon-2026-0050_ref_012","doi-asserted-by":"crossref","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378: 2078-92. doi: 10.1056\/NEJMoa1801005","DOI":"10.1056\/NEJMoa1801005"},{"key":"2026090905570684855_j_raon-2026-0050_ref_013","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040-51. doi: 10.1056\/NEJMoa1810865","DOI":"10.1056\/NEJMoa1810865"},{"key":"2026090905570684855_j_raon-2026-0050_ref_014","doi-asserted-by":"crossref","unstructured":"Mathew M, Safyan RA, Shu CA. PD-L1 as a biomarker in NSCLC: challenges and future directions. Ann Transl Med 2017; 5: 375. doi: 10.21037\/atm.2017.08.04","DOI":"10.21037\/atm.2017.08.04"},{"key":"2026090905570684855_j_raon-2026-0050_ref_015","doi-asserted-by":"crossref","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37: 537-46. doi: 10.1200\/JCO.18.00149","DOI":"10.1200\/JCO.18.00149"},{"key":"2026090905570684855_j_raon-2026-0050_ref_016","doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fclop A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 Tumor Proportion Score \u2265 50%. J Clin Oncol 2021; 39: 2339-49. doi: 10.1200\/JCO.21.00174","DOI":"10.1200\/JCO.21.00174"},{"key":"2026090905570684855_j_raon-2026-0050_ref_017","doi-asserted-by":"crossref","unstructured":"Amrane K, Geier M, Corre R, L\u00e9veiller G, Florence G, Lamy R, et al. First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort. Ann Oncol 2019; 30: v617. doi: 10.1093\/annonc\/mdz260","DOI":"10.1093\/annonc\/mdz260.024"},{"key":"2026090905570684855_j_raon-2026-0050_ref_018","doi-asserted-by":"crossref","unstructured":"Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). Invest New Drugs 2019; 37: 1266-73. doi: 10.1007\/s10637-019-00843-y","DOI":"10.1007\/s10637-019-00843-y"},{"key":"2026090905570684855_j_raon-2026-0050_ref_019","doi-asserted-by":"crossref","unstructured":"Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F, et al. Clinicopathologic Correlates of First-Line Pembrolizumab Effectiveness in Patients With Advanced NSCLC and a PD-L1 Expression of \u2265 50. Cancer Immunol Immunother 2020; 69: 2209-21. doi: 10.1007\/s00262-020-02613-9","DOI":"10.1007\/s00262-020-02613-9"},{"key":"2026090905570684855_j_raon-2026-0050_ref_020","doi-asserted-by":"crossref","unstructured":"Velcheti V, Chandwani S, Chen X, Pietanza MC, Piperdi B, Burke T. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS\u226550%) metastatic NSCLC at US oncology practices. Immunotherapy 2019; 11: 1541-54. doi: 10.2217\/imt-2019-0177","DOI":"10.2217\/imt-2019-0177"},{"key":"2026090905570684855_j_raon-2026-0050_ref_021","doi-asserted-by":"crossref","unstructured":"Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol 2019; 30: 1653-59. doi: 10.1093\/annonc\/mdz288","DOI":"10.1093\/annonc\/mdz288"},{"key":"2026090905570684855_j_raon-2026-0050_ref_022","doi-asserted-by":"crossref","unstructured":"Shah M, Marmarelis ME, Mamtani M, Hennessy S. Association between survival and very high versus high PD-L1 expression in patients receiving pembrolizumab as first-line treatment for advanced non-small cell lung cancer. Clin Lung Cancer 2022; 23: 731-6. doi: 10.1016\/j.cllc.2022.07.003","DOI":"10.1016\/j.cllc.2022.07.003"},{"key":"2026090905570684855_j_raon-2026-0050_ref_023","doi-asserted-by":"crossref","unstructured":"Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, et al. Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%\u201389%) versus very high (\u2265 90 %) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab. JTO Clin Res Rep 2024; 5: 100675. doi: 10.1016\/j.jtocrr.2024.100675","DOI":"10.1016\/j.jtocrr.2024.100675"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2026-0050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:26:10Z","timestamp":1788953170000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2026-0050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.2478\/raon-2026-0050"],"URL":"https:\/\/doi.org\/10.2478\/raon-2026-0050","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}